(AOF) – genOway announces having achieved consolidated turnover of 20 million euros in 2023, organic growth of 18% compared to 2022. This company specializes in the design, development and marketing of research models preclinical genetically modified to contribute to the invention of drugs specifies that its Ebitda increased by 54% in 2023 to 4.6 million euros and that the Ebitda margin stands at 23.0% in 2023, compared to 18.8 % one year earlier. Net profit doubled to 1.6 million euros in 2023 compared to 0.8 million in 2022.
As of December 31, 2023, genOway’s equity amounted to 16.5 million euros and the level of available cash was 4.3 million euros (excluding 2022 research tax credit of 2.7 million euros). euros paid in January 2024).
By 2028, the company is targeting a turnover of at least 50 million euros, i.e. organic growth of 20% per year, and each year a gross margin greater than 50% and an Ebitda margin. greater than 15%. It also aims to self-finance its development.
AOF – LEARN MORE
Learn more about the Pharmacy sector
Oncology, priority of pharmaceutical giants
Sanofi’s stock market disappointment recorded at the end of October 2023 underlines the new direction for the group, which has now set oncology as its number 1 priority. Efforts in this segment, where therapies are advancing the fastest, notably involve investments in R&D which weigh on profitability. Sanofi therefore announced a drop in its earnings per share in 2024 and the abandonment of its objective of an operating margin of 32% in 2025. Merck has just unveiled a new alliance. It will pay up to $22 billion to the Japanese group Daiichi Sankyo as part of a partnership on experimental cancer treatments. While some experts estimate that the United States represents nearly half of global oncology spending (drugs and treatments), or $196 billion in 2022, Chinese spending in this area has more than doubled in five years, going from 5 to 11.8 billion dollars.